Simulated microgravity alters rat mesenteric artery vasoconstrictor dynamics through an intracellular Ca(2+) release mechanism.
Previous work has shown that orthostatic hypotension associated with cardiovascular deconditioning results from inadequate peripheral vasoconstriction. We used the hindlimb-unloaded (HU) rat in this study as a model to induce cardiovascular deconditioning. The purpose of this study was to test the hypothesis that 14 days of HU diminishes vasoconstrictor responsiveness of mesenteric resistance arteries. Mesenteric resistance arteries from control (n = 43) and HU (n = 44) rats were isolated, cannulated, and pressurized to 108 cm H(2)O for in vitro experimentation. Myogenic (intralumenal pressure ranging from 30 to 180 cm H(2)O), KCl (2-100 mM), norepinephrine (NE, 10(-9)-10(-4) M) and caffeine (1-20 mM) induced vasoconstriction, as well as the temporal dynamics of vasoconstriction to NE, were determined. The active myogenic and passive pressure responses were unaltered by HU when pressures remained within physiological range. However, vasoconstrictor responses to KCl, NE, and caffeine were diminished by HU, as well as the rate of constriction to NE (C, 14.8 +/- 3.6 microm/s vs. HU 7.6 +/- 1.8 microm/s). Expression of sarcoplasmic reticulum Ca(2+)ATPase 2 and ryanodine 3 receptor mRNA was unaffected by HU, while ryanodine 2 receptor mRNA and protein expression were diminished in mesenteric arteries from HU rats. These data suggest that HU-induced and microgravity-associated orthostatic intolerance may be due, in part, to an attenuated vasoconstrictor responsiveness of mesenteric resistance arteries resulting from a diminished ryanodine 2 receptor Ca(2+) release mechanism.
Colleran
Patrick N
PN
Department of Health and Kinesiology, Texas A&M University, College Station, TX, USA.
Behnke
Bradley J
BJ
Wilkerson
M Keith
MK
Donato
Anthony J
AJ
Delp
Michael D
MD
D000818:Animals; D015153:Blotting, Western; D001835:Body Weight / Q000502:physiology; D002110:Caffeine / Q000494:pharmacology; D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology*; D002196:Capillaries / Q000502:physiology; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D019417:Hindlimb Suspension; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects / Q000502:physiology*; D018482:Muscle, Skeletal / Q000033:anatomy & histology / Q000502:physiology; D009638:Norepinephrine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology*; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D018474:Weightlessness Simulation
D000697:Central Nervous System Stimulants; D012333:RNA, Messenger; D014662:Vasoconstrictor Agents; D002110:Caffeine; D011189:Potassium Chloride; D009638:Norepinephrine